Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan
Japan approval of subcutaneous KEYTRUDA QLEX for all indications signals expanded Merck oncology access.
What changed
Japan approval of subcutaneous KEYTRUDA QLEX for all indications signals expanded Merck oncology access.
Why it matters
Japan approval of subcutaneous KEYTRUDA QLEX for all indications signals expanded Merck oncology access. — impact context not separately stored; see What changed.
← Dashboard
Sep 21, 2026 11:06 AM ET